-2.0%
XLC vs MRNA
+485.7%
-487.8%
-11.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.0% | +5.4% | -4.4% | +0.9% |
| 7D | +0.5% | -1.1% | +1.6% | +0.5% |
| 30D | +2.1% | +126.1% | -124.0% | +0.7% |
| 3M | +0.7% | +190.0% | -189.3% | -1.9% |
| 6M | -3.2% | +157.2% | -160.4% | -5.4% |
| YTD | -3.8% | +388.2% | -392.0% | -7.5% |
| 1Y | -2.0% | +467.0% | -469.1% | -6.0% |
| All | -2.0% | +485.7% | -487.8% | -6.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling